Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19

Wang et al., medRxiv, doi:10.1101/2021.06.01.21258147
Jun 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 100 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19ivm.org
Analysis of the manufacturing cost of several COVID-19 medications, showing a cost of $0.55 per course of ivermectin, including excipients, formulation, tax, and profit.
Wang et al., 3 Jun 2021, preprint, 4 authors.
This PaperIvermectinAll
Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19
Junzheng Wang, Jacob Levi, Leah Ellis, Dr Andrew Hill
doi:10.1101/2021.06.01.21258147
Background Currently, only dexamethasone, tocilizumab and sarilumab have conclusively been shown to reduce mortality of COVID-19. Safe and effective treatments will need to be both affordable and widely available globally to be used alongside vaccination programmes. This analysis will estimate and compare potential generic minimum costs of a selection of approved COVID-19 drug candidates with available international list prices. Methods: We searched for repurposed drugs that have been approved by at least one of the WHO, FDA or NICE, or at least given emergency use authorisation or recommended for off-label prescription. Drug prices were searched for, for dexamethasone, budesonide, baricitinib, tocilizumab, casirivimab and imdevimab, and sarilumab using active pharmaceutical ingredients (API) data extracted from global shipping records. This was compared with national pricing data from a range of low, medium, and high-income countries. Annual API export volumes from India were used to estimate the current availability of each drug. Results: Repurposed therapies can be generically manufactured for some treatments at
Conflicts of interest: None to declare.
References
Ahlqvist, Mcgeough, Senanayake, Armstrong, Yadaw et al., Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine, ACS Omega, doi:10.1021/acsomega.1c00772
Barber, Dzintars, Estimated cost-based generic prices for molnupiravir for the treatment of COVID-19 infection
Bhuyan, In India, black markets for tocilizumab spring up as demand for the Covid-19 drug surges
Eaton, Covid-19: WHO warns against "vaccine nationalism" or face further virus mutations, BMJ, doi:10.1136/bmj.n292
Gotham, Barber, Hill, Estimation of cost-based prices for injectable medicines in the WHO Essential Medicines List, BMJ Open
Group, Yu, Bafadhel, Dorward, Hayward et al., Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial, doi:10.1101/2021.04.10.21254672
Hill, Barber, Gotham, Estimated costs of production and potential prices for the WHO Essential Medicines List, BMJ Global Health
Hill, Garratt, Levi, Falconer, Ellis et al., Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
Hill, Simmons, Gotham, Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C, J Virus Erad
Hill, Wang, Levi, Minimum costs to manufacture new treatments for COVID-19
Horby, Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, doi:10.1016/S0140-6736(21)00149-5
Horby, Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label
Horby, Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label
Horby, Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2022926
Horby, Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, doi:10.1016/S0140-6736(20)32013-4
Investigators, Gordon, Mouncey, Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2100433
Kalil, Patterson, Mehta, Baricitinib plus remdesivir for hospitalized adults with Covid-19, New England Journal of Medicine
Khan, Stewart, Fabbri, Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19, Thorax. Published Online First, doi:10.1136/thoraxjnl-2020-215266
Klutz, Holtmann, Lobedann, Cost evaluation of antibody production processes in different operation modes, Chemical Engineering Science
Love, The production of generic drugs in India, BMJ
Mahase, Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports, BMJ
Moon, Jambert, Childs, A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries, Global Health, doi:10.1186/1744-8603-7-39
Mullard, Flooded by the torrent: the COVID-19 drug pipeline, Lancet, doi:10.1016/S0140-6736(20)30894-1
New, Revise Biosimilar Guidelines, Scientists Demand; WHO Says Not Now
Pan, Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results, N Engl J Med, doi:10.1056/NEJMoa2023184
Popp, Stegemann, Metzendorf, Gould, Kranke et al., Ivermectin for preventing and treating COVID-19, Cochrane Database of Systematic Reviews, doi:10.1002/14651858.CD015017.pub2
Ramakrishnan, Jr, Langford, Mahdi, Jeffers et al., Inhaled in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial, Lancet Respiratory Medicine
Recovery Collaborative, Dexamethasone in hospitalized patients with Covid-19, New England Journal of Medicine
Simoens, Vulto, A health economic guide to market access of biosimilars, Expert Opin Biol Ther, doi:10.1080/14712598.2021.1849132
Stebbing, Phelan, Griffin, COVID-19: combining antiviral and antiinflammatory treatments, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30132-8
Tardif, Bouabdallaoui, Allier, randomised, double-blinded, adaptive, placebocontrolled, multicentre trial
Weinreich, Sivapalasingam, Norton, Ali, Gao et al., REGEN-COV antibody cocktail clinical outcomes study in Covid-19 outpatients
Wire, Governments Spent at Least €93bn on COVID-19 Vaccines and Therapeutics During the Last 11 Months
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit